SAM
CMPX icon

Smartleaf Asset Management’s Compass Therapeutics CMPX Stock Holding History

Smartleaf Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149 Hold
69
– – ﹤0.01% 3332
2026
Q1 		$352 Hold
69
– – ﹤0.01% 3272
2025
Q4 		$371 Buy
+69
New +$319 ﹤0.01% 3296

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Smartleaf Asset Management's CMPX Position: Q2 2026 in Review

Smartleaf Asset Management held its Compass Therapeutics (CMPX) position steady in Q2 2026 at 69 shares worth $149. The position accounts for ﹤0.01% of the portfolio, ranked #3332.

Smartleaf Asset Management first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. The position peaked at $371 in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Smartleaf Asset Management held 69 shares of Compass Therapeutics worth $149 as of Q2 2026.
  • Smartleaf Asset Management left its Compass Therapeutics share count unchanged in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3332 holding.
  • Smartleaf Asset Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Smartleaf Asset Management's Compass Therapeutics position peaked at $371 in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.